GLP-1 Peptide Atlas, by Delfa

TerminatedPhase 1

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Lead sponsor

Profil Institut für Stoffwechselforschung GmbH

Assets

Liraglutide / Lixisenatide

Listed sites

Recruiting sites

—

Enrollment

109

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Change from baseline (week -1) in the number of reflux episodes

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02231658

Org study IDGI-Motil

Timeline

Milestones

Study first posted2014-09-04estimated

Study start2015-07-16actual

Primary completion2018-07-23actual

Study completion2018-07-23actual

Last update posted2018-10-17actual

Assets

Investigational agents

Liraglutide Lixisenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.

•Male or female aged 18-65 years (both inclusive)

•T2DM diagnosis

Exclusion criteria

•Contraindications (including known or suspected hypersensitivity) to GLP-1 mimetics

•Use of GLP-1 mimetics or DPP-IV inhibitors

•Clinically relevant dysglycaemia as indicated by HbA1C ≥ 10%

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other clinical outcomes

2 endpoints

Primary/protocol endpoint

Change from baseline (week -1) in the number of reflux episodes

Time frame:24 hours after 10 weeks of treatment

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline (week -1) in the time of pH < 4.0 in the lower third of the oesophagus

Time frame:After 10 weeks of treatment

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
Diabetes care2020 Sep (month)PMID32647054doi:10.2337/dc20-0720via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.